KR100801207B1 - 분지-사슬 친지질성 분자의 유도체 및 그것의 사용 - Google Patents

분지-사슬 친지질성 분자의 유도체 및 그것의 사용 Download PDF

Info

Publication number
KR100801207B1
KR100801207B1 KR1020037001485A KR20037001485A KR100801207B1 KR 100801207 B1 KR100801207 B1 KR 100801207B1 KR 1020037001485 A KR1020037001485 A KR 1020037001485A KR 20037001485 A KR20037001485 A KR 20037001485A KR 100801207 B1 KR100801207 B1 KR 100801207B1
Authority
KR
South Korea
Prior art keywords
bfa
delete delete
pharmaceutical composition
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037001485A
Other languages
English (en)
Korean (ko)
Other versions
KR20030024823A (ko
Inventor
알렉산더 코작
마리나 빈니코바
미카엘 폴리악
엘리에제르 베이트-얀나이
달리아 레즈니트스키-코헨
알렉산더 센데리킨
Original Assignee
디-팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디-팜 리미티드 filed Critical 디-팜 리미티드
Publication of KR20030024823A publication Critical patent/KR20030024823A/ko
Application granted granted Critical
Publication of KR100801207B1 publication Critical patent/KR100801207B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020037001485A 2000-08-03 2001-08-01 분지-사슬 친지질성 분자의 유도체 및 그것의 사용 Expired - Fee Related KR100801207B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL137672 2000-08-03
IL13767200A IL137672A0 (en) 2000-08-03 2000-08-03 Derivatives of branched-chain lipophilic molecules and uses thereof
PCT/IL2001/000713 WO2002011666A2 (en) 2000-08-03 2001-08-01 Derivatives of branched-chain lipophilic molecules and uses thereof

Publications (2)

Publication Number Publication Date
KR20030024823A KR20030024823A (ko) 2003-03-26
KR100801207B1 true KR100801207B1 (ko) 2008-02-05

Family

ID=11074480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037001485A Expired - Fee Related KR100801207B1 (ko) 2000-08-03 2001-08-01 분지-사슬 친지질성 분자의 유도체 및 그것의 사용

Country Status (16)

Country Link
US (2) US7186703B2 (https=)
EP (1) EP1305322B1 (https=)
JP (1) JP2004505898A (https=)
KR (1) KR100801207B1 (https=)
CN (1) CN100467476C (https=)
AT (1) ATE455120T1 (https=)
AU (2) AU2001280043B2 (https=)
BR (1) BR0112835A (https=)
CA (1) CA2416808C (https=)
CZ (1) CZ2003208A3 (https=)
DE (1) DE60141074D1 (https=)
ES (1) ES2338987T3 (https=)
HU (1) HUP0301711A3 (https=)
IL (1) IL137672A0 (https=)
NZ (1) NZ523664A (https=)
WO (1) WO2002011666A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
MXPA03002934A (es) 2000-10-10 2004-05-04 Univ North Carolina Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
AU2006249347A1 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
US8236820B2 (en) * 2007-08-10 2012-08-07 Basil Rigas Anti-inflammatory compounds and uses thereof
JP2011513318A (ja) * 2008-02-28 2011-04-28 ヘンリ フオルド ヘルス システム 中枢神経系損傷の治療を強化するために間質細胞を使用する組成物及び方法
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
JP5853869B2 (ja) * 2012-06-07 2016-02-09 日油株式会社 ホスホリルコリン基含有化合物及びその製造法
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3260688A (en) 1962-08-10 1966-07-12 Toyo Koatsu Ind Inc Resin compositions for producing cellular masses and process for producing a cellular product
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
JPS63122775A (ja) 1986-11-12 1988-05-26 Kao Corp 油ゲル化剤
JPH01290604A (ja) * 1988-05-18 1989-11-22 Dai Ichi Kogyo Seiyaku Co Ltd 水中崩壊性良好な農薬粒剤
JP2000053897A (ja) * 1998-08-07 2000-02-22 Kao Corp インクジェット記録用水系インク

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006946A (en) * 1953-03-04 1961-10-31 Union Carbide Corp Production of heterocyclic phosphoruscontaining compounds and products
US3260668A (en) * 1964-11-04 1966-07-12 Dow Chemical Co Alkaline scale control in saline water conversion equipment
DE2038829C3 (de) * 1970-08-05 1975-11-13 Chemische Werke Huels Ag, 4370 Marl Zusatzmittel zu Mörtel oder Beton auf Zementbasis
LU65735A1 (https=) 1972-07-17 1974-01-28
DE2930756A1 (de) 1979-07-28 1981-02-26 Cassella Ag Klotzhilfsmittel und verfahren zum faerben von cellulosefasern bzw. gemischen von cellulosefasern zusammen mit synthesefasern mit schwefel-, schwefelkuepen-, kuepen- und reaktivfarbstoffen
JPS6038363B2 (ja) 1979-11-27 1985-08-31 ライオン株式会社 ヘアリンス剤
JPS5716064A (en) * 1980-07-04 1982-01-27 Dai Ichi Kogyo Seiyaku Co Ltd Dye dispersion
JPS57112317A (en) * 1980-12-29 1982-07-13 Lion Corp Hairdressing agent composition
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
JPS6072829A (ja) 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法
JPH0832832B2 (ja) 1984-03-09 1996-03-29 花王株式会社 加熱瀝青質用添加剤
JPS61129189A (ja) 1984-11-28 1986-06-17 Kao Corp リン酸エステルまたはその塩の精製方法
US4736051A (en) 1985-03-20 1988-04-05 Kao Corporation Process for the preparation of an alkali metal salt of a diester phosphoric acid
US4751320A (en) 1985-11-27 1988-06-14 Kao Corporation Phosphoric ester and process for producing same
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
JPS62177008A (ja) 1986-01-29 1987-08-03 Kao Corp 共重合体の製造法
WO1989011299A1 (en) 1988-05-18 1989-11-30 State Of Oregon Acting By And Through The State Bo Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
US5059415A (en) 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
FR2677360B1 (fr) 1991-06-05 1995-04-14 Atta Composes amphiphiles perfluoroalkyles du phosphore, leurs preparations et leurs applications notamment dans le domaine biomedical.
US5846516A (en) * 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
JP2710900B2 (ja) * 1992-09-02 1998-02-10 株式会社ディ・ディ・エス研究所 酸性官能基を有する脂質誘導体及び同誘導体によって被覆された微粒子キャリヤー
US5491004A (en) * 1994-05-26 1996-02-13 Henkel Corporation Process for applying a low soiling fiber finish
US5686540A (en) * 1995-09-29 1997-11-11 Dainippon Ink And Chemicals, Inc. Process for the preparation of lactic acid-based polyester
JP3747091B2 (ja) * 1996-03-22 2006-02-22 株式会社クラブコスメチックス アポトーシス誘導剤
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
WO1998055487A1 (en) * 1997-06-04 1998-12-10 Biocompatibles Limited Phosphate compounds
AU7781498A (en) * 1997-06-04 1998-12-21 Biocompatibles Limited Zwitterionic compounds and their use to cross-link collagenous materials
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
IL121269A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3260688A (en) 1962-08-10 1966-07-12 Toyo Koatsu Ind Inc Resin compositions for producing cellular masses and process for producing a cellular product
US4670575A (en) * 1984-06-05 1987-06-02 Kao Corporation Process for purification of phosphoric mono esters
JPS63122775A (ja) 1986-11-12 1988-05-26 Kao Corp 油ゲル化剤
JPH01290604A (ja) * 1988-05-18 1989-11-22 Dai Ichi Kogyo Seiyaku Co Ltd 水中崩壊性良好な農薬粒剤
JP2000053897A (ja) * 1998-08-07 2000-02-22 Kao Corp インクジェット記録用水系インク

Also Published As

Publication number Publication date
CN1633440A (zh) 2005-06-29
JP2004505898A (ja) 2004-02-26
US20070135381A1 (en) 2007-06-14
EP1305322A2 (en) 2003-05-02
CZ2003208A3 (cs) 2003-10-15
ATE455120T1 (de) 2010-01-15
CN100467476C (zh) 2009-03-11
AU2001280043B8 (en) 2002-02-18
WO2002011666A3 (en) 2002-07-11
AU8004301A (en) 2002-02-18
DE60141074D1 (de) 2010-03-04
HUP0301711A3 (en) 2007-05-29
ES2338987T3 (es) 2010-05-14
CA2416808C (en) 2011-11-22
WO2002011666A2 (en) 2002-02-14
IL137672A0 (en) 2001-10-31
CA2416808A1 (en) 2002-02-14
US7687483B2 (en) 2010-03-30
KR20030024823A (ko) 2003-03-26
EP1305322A4 (en) 2005-04-13
HUP0301711A2 (hu) 2003-09-29
EP1305322B1 (en) 2010-01-13
AU2001280043B2 (en) 2007-05-24
NZ523664A (en) 2004-07-30
BR0112835A (pt) 2003-10-21
US7186703B2 (en) 2007-03-06
US20030186897A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
KR100801207B1 (ko) 분지-사슬 친지질성 분자의 유도체 및 그것의 사용
AU2001280043A1 (en) Derivatives of branched-chain lipophilic molecules and uses thereof
CN105705152B (zh) 基于脂质的铂化合物和纳米粒子
Zhou et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer
KR100386002B1 (ko) 소수성탁산유도체
ES2241872T3 (es) Sales del promedicamento combretastatina a-4 con compuestos que contienen nitrogeno.
ES2492496T3 (es) Derivados de etoxi-difeniletano, procesos de preparación y usos del mismo
KR20010079627A (ko) 힌더드 알콜 또는 페놀의 수용성 프로드럭
EP1389970A2 (en) Compositions and methods of double-targeting virus infections and cancer cells
WO2015117136A1 (en) Boronic acid esters and pharmaceutical formulations thereof
WO2008119032A1 (en) Compositions and methods for protecting cells from toxic exposures
Jendrossek et al. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro.
ES2703740T3 (es) Compuestos de organoarsénico y procedimientos para el tratamiento del cáncer
Jackson et al. The antineoplastic ether lipid, s-phosphonate, selectively induces apoptosis in human leukemic cells and exhibits antiangiogenic and apoptotic activity on the chorioallantoic membrane of the chick embryo
Zhu et al. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo
CN120359207A (zh) 一种阳离子脂质材料的制备及应用
WO2019020072A1 (en) ERIANINE DERIVATIVES AND THEIR USE
JPWO2014196621A1 (ja) 抗癌剤
KR102486721B1 (ko) 신규 mTOR 억제제 화합물 및 이의 용도
CN109824623A (zh) 一种单去甲氧基姜黄素吡咯衍生物及其制备方法和用途
WO2014151697A1 (en) Therapeutic uses for geranylgeranyl acetone and derivatives thereof
Krise A novel prodrug approach for tertiary amines: synthesis and evaluation of N-phosphonooxymethyl derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080408

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1008012070000

Gazette reference publication date: 20080205

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120110

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130130

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130130